Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.

ABSTRACT: Cytotoxic T lymphocyte (CTL) epitope peptide-based vaccines are widely used in cancer and infectious disease therapy. We previously generated an immune-tolerant elastin-like polypeptides (iTEPs)-based carrier to deliver a peptide CTL vaccine and enhance the efficiency of the vaccine. To further optimize the vaccine carrier, we intended to potentiate its function by designing an iTEP-based carrier that was able to deliver adjuvant and a vaccine epitope as one molecule. Thus, we fused a 9-mer H₁₀₀, a peptide derived from the high-mobility group box 1 protein (HMGB1) that could induce activation of dendritic cells (DCs), with an iTEP polymer to generate a new iTEP polymer named H₁₀₀-iTEP. The H₁₀₀-iTEP still kept the feature of reversible phase transition of i

SUBMITTER: Dong S 

PROVIDER: S-EPMC5520189 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature